1. Home
  2. MDGL vs BGC Comparison

MDGL vs BGC Comparison

Compare MDGL & BGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • BGC
  • Stock Information
  • Founded
  • MDGL 2011
  • BGC 1945
  • Country
  • MDGL United States
  • BGC United States
  • Employees
  • MDGL N/A
  • BGC N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • BGC Investment Bankers/Brokers/Service
  • Sector
  • MDGL Health Care
  • BGC Finance
  • Exchange
  • MDGL Nasdaq
  • BGC Nasdaq
  • Market Cap
  • MDGL 6.1B
  • BGC 5.0B
  • IPO Year
  • MDGL N/A
  • BGC 1999
  • Fundamental
  • Price
  • MDGL $440.75
  • BGC $9.85
  • Analyst Decision
  • MDGL Strong Buy
  • BGC Strong Buy
  • Analyst Count
  • MDGL 10
  • BGC 2
  • Target Price
  • MDGL $474.67
  • BGC $14.50
  • AVG Volume (30 Days)
  • MDGL 341.0K
  • BGC 2.2M
  • Earning Date
  • MDGL 10-30-2025
  • BGC 10-30-2025
  • Dividend Yield
  • MDGL N/A
  • BGC 0.83%
  • EPS Growth
  • MDGL N/A
  • BGC 38.47
  • EPS
  • MDGL N/A
  • BGC 0.30
  • Revenue
  • MDGL $515,547,000.00
  • BGC $2,473,844,000.00
  • Revenue This Year
  • MDGL $394.12
  • BGC $36.11
  • Revenue Next Year
  • MDGL $57.74
  • BGC $11.13
  • P/E Ratio
  • MDGL N/A
  • BGC $32.08
  • Revenue Growth
  • MDGL 3421.98
  • BGC 20.94
  • 52 Week Low
  • MDGL $200.63
  • BGC $7.24
  • 52 Week High
  • MDGL $457.16
  • BGC $11.79
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 62.88
  • BGC 46.72
  • Support Level
  • MDGL $415.53
  • BGC $9.89
  • Resistance Level
  • MDGL $440.90
  • BGC $10.27
  • Average True Range (ATR)
  • MDGL 14.27
  • BGC 0.25
  • MACD
  • MDGL -4.71
  • BGC -0.02
  • Stochastic Oscillator
  • MDGL 60.58
  • BGC 42.11

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

About BGC BGC Group Inc.

BGC Group Inc is a brokerage and financial technology company that serves financial markets, energy, and commodities markets. Its service and product offerings include brokerage for a wide range of financial products, including fixed income, equities, commodities, derivatives, and real estate, software solutions for trading platforms, clearing, trade execution, and other back-office services. Its clients mostly include banks, financial institutions, and corporate clients. BGC operates in one reportable segment, which is providing brokerage services. Geographically, the company generates a majority of its revenue from Europe, Middle East and Africa (EMEA), followed by the Americas and the Asia-Pacific region.

Share on Social Networks: